More election risk
HOW long do I have to wait for a resolution to this?
In an online Barron's piece discussing Thursday's rally, Morgan Stanley analyst Jami Rubin echoes some of the same themes I wrote about on Friday. Ms. Rubin focuses on foreign importation, which I addressed, and a removal of the prohibition on government's ability to negotiate drug prices, which I did not because I don't think it is as significant a risk to the sector even if it is one of the more likely changes under a Democratic administration.
When the market feels ill, we usually get a rotation into drug stocks. I read several stories over the last few weeks quoting people who were surprised at the lack of rotation into this group. Election risk is the likely reason rotational dollars are going elsewhere.
Ms. Rubin concludes by recommending Pfizer (PFE:NASD) and Wyeth (WYE:NASD). We're about education and not recommendation here at Minyanville. Furthermore, I'll be the first to admit I understand trading dynamics of dev-stage biotechs much better than I do trading dynamics for big pharma. But, I'd be remiss if I didn't point out the issue of election risk throws a big wildcard into any growth forecasts for pharma sales. Caveat emptor.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter